PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34690927-0	2021	Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?	Clomiphene	101-119	cytochrome P450 2D6	Homo sapiens	6-25
31691978-5	2019	The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 mul/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 mul/min/mg protein, respectively.	dihydrocodeine	33-47	cytochrome P450 2D6	Homo sapiens	86-105
34520032-5	2021	Among the atypical opioids, tramadol has an advantage of being a Schedule IV drug, and thus having a relatively low abuse potential-but its effects, including its effect on respiratory drive, are dependent on cytochrome P450 2D6 metabolizer status.	Tramadol	28-36	cytochrome P450 2D6	Homo sapiens	209-228
31828069-0	2019	Conversion of Cytochrome P450 2D6 of Human Into a FRET-Based Tool for Real-Time Monitoring of Ajmalicine in Living Cells.	raubasine	94-104	cytochrome P450 2D6	Homo sapiens	14-33
31828069-6	2019	Given this, the present study was conducted to develop a genetically encoded FRET-based nanosensor by engineering human Cytochrome P450-2D6, an ajmalicine binding protein.	raubasine	144-154	cytochrome P450 2D6	Homo sapiens	120-139
33312997-5	2020	LEARNING POINTS: Paliperidone and mirtazapine are associated with first-degree heart block, which may be a harbinger of torsades de pointes and ventricular fibrillation.Paliperidone and mirtazapine may potentiate each other"s proarrhythmic effects since the metabolism of both involve the cytochrome P450 2D6 enzyme.A history of psychiatric illness makes it difficult to rule out atypical chest pain without ECG or troponins and often leads to increased resource utilization, even during times of heavy use like the COVID-19 pandemic.	Paliperidone Palmitate	17-29	cytochrome P450 2D6	Homo sapiens	289-308
33312997-5	2020	LEARNING POINTS: Paliperidone and mirtazapine are associated with first-degree heart block, which may be a harbinger of torsades de pointes and ventricular fibrillation.Paliperidone and mirtazapine may potentiate each other"s proarrhythmic effects since the metabolism of both involve the cytochrome P450 2D6 enzyme.A history of psychiatric illness makes it difficult to rule out atypical chest pain without ECG or troponins and often leads to increased resource utilization, even during times of heavy use like the COVID-19 pandemic.	Mirtazapine	34-45	cytochrome P450 2D6	Homo sapiens	289-308
33312997-5	2020	LEARNING POINTS: Paliperidone and mirtazapine are associated with first-degree heart block, which may be a harbinger of torsades de pointes and ventricular fibrillation.Paliperidone and mirtazapine may potentiate each other"s proarrhythmic effects since the metabolism of both involve the cytochrome P450 2D6 enzyme.A history of psychiatric illness makes it difficult to rule out atypical chest pain without ECG or troponins and often leads to increased resource utilization, even during times of heavy use like the COVID-19 pandemic.	Mirtazapine	186-197	cytochrome P450 2D6	Homo sapiens	289-308
31691978-5	2019	The in vitro Vmax /Km values for dihydrocodeine demethylation mediated by recombinant cytochrome P450 2D6 and 3A4 were 0.19 and 0.066 mul/min/pmol, respectively, and for dihydrocodeine 6-O-glucuronidation mediated by recombinant UGT2B4 and 2B7, the Vmax /Km values were 0.14 and 0.22 mul/min/mg protein, respectively.	dihydrocodeine	170-184	cytochrome P450 2D6	Homo sapiens	86-105
26088654-0	2015	Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?	Atomoxetine Hydrochloride	110-121	cytochrome P450 2D6	Homo sapiens	54-73
30412271-9	2019	palonosetron is metabolized by cytochrome P450 2D6 to 2 major substantially inactive metabolites (M4 and M9).	Palonosetron	0-12	cytochrome P450 2D6	Homo sapiens	31-50
30828021-5	2019	This decision was based on concerns about the effects of the extensive metabolite morphine in cytochrome P450 2D6 ultra-rapid metabolizers.	Morphine	82-90	cytochrome P450 2D6	Homo sapiens	94-113
30349215-6	2018	In addition, the therapeutic response to donepezil may be influenced by apolipoprotein E or cytochrome P450 2D6 polymorphism.	Donepezil	41-50	cytochrome P450 2D6	Homo sapiens	92-111
25774703-1	2015	BACKGROUND: The polymorphic nature of cytochrome P450 2D6 has made therapeutic drug monitoring of the anti-anginal agent perhexiline a compulsory step in reducing adverse events associated with plasma concentrations above the therapeutic range (0.15-0.60 mg/L).	Perhexiline	121-132	cytochrome P450 2D6	Homo sapiens	38-57
24894748-8	2015	By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol"s clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.	Terbinafine	39-50	cytochrome P450 2D6	Homo sapiens	18-37
24894748-8	2015	By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol"s clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.	Metoprolol	65-75	cytochrome P450 2D6	Homo sapiens	18-37
24894748-8	2015	By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol"s clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.	Metoprolol	100-110	cytochrome P450 2D6	Homo sapiens	18-37
27046219-8	2017	Duloxetine and bupropion are both cytochrome P450 2D6 inhibitors that may result in a higher level of hydroxybupropion.	Duloxetine Hydrochloride	0-10	cytochrome P450 2D6	Homo sapiens	34-53
27046219-8	2017	Duloxetine and bupropion are both cytochrome P450 2D6 inhibitors that may result in a higher level of hydroxybupropion.	Bupropion	15-24	cytochrome P450 2D6	Homo sapiens	34-53
27046219-8	2017	Duloxetine and bupropion are both cytochrome P450 2D6 inhibitors that may result in a higher level of hydroxybupropion.	hydroxybupropion	102-118	cytochrome P450 2D6	Homo sapiens	34-53
27800629-1	2017	WHAT IS KNOWN AND OBJECTIVE: Polymorphisms in cytochrome P450 2D6 and 2C19 can lead to interindividual differences in drug plasma concentrations, affecting clomipramine efficacy.	Clomipramine	156-168	cytochrome P450 2D6	Homo sapiens	46-74
24717054-0	2014	Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.	Tramadol	65-73	cytochrome P450 2D6	Homo sapiens	134-153
25127601-0	2014	Cytochrome P450 2D6 based electrochemical sensor for the determination of codeine.	Codeine	74-81	cytochrome P450 2D6	Homo sapiens	0-19
25127601-1	2014	Considering the enzymatic activity of the cytochrome P450 2D6 on substrates such as codeine, the current paper includes the development of an enzymatic biosensor for detection of this drug.	Codeine	84-91	cytochrome P450 2D6	Homo sapiens	42-61
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Quinidine	4-13	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	27-29	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	q	30-31	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	98-114	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextrorphan	140-151	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextromethorphan	172-188	cytochrome P450 2D6	Homo sapiens	45-64
25061302-4	2014	The quinidine component of DM/Q inhibits the cytochrome P450 2D6-mediated metabolic conversion of dextromethorphan to its active metabolite dextrorphan, thereby increasing dextromethorphan systemic bioavailability and driving the pharmacology toward that of the parent drug and away from adverse effects of the dextrorphan metabolite.	Dextrorphan	311-322	cytochrome P450 2D6	Homo sapiens	45-64
24413750-8	2014	We show that using this workflow, binding affinities of aryloxypropanolamines to the malleable Cytochrome P450 2D6 enzyme can be predicted without a priori knowledge of dominant protein-ligand conformations.	aryloxypropanolamines	56-77	cytochrome P450 2D6	Homo sapiens	95-114
26000221-6	2014	To block DM hepatic metabolism, thereby increasing DM bioavailability, Quinidine, a cytochrome P450 2D6 inhibitor, is coadministered at a dosage well below those for treating cardiac arrhythmia.	Quinidine	71-80	cytochrome P450 2D6	Homo sapiens	84-103
24007891-4	2013	This case highlights the incidence of depression in persons with breast cancer, examines the controversy of tamoxifen-induced depression, and evaluates antidepressant considerations regarding potentially efficacy-reducing cytochrome P450 2D6 drug interactions with tamoxifen.	Tamoxifen	265-274	cytochrome P450 2D6	Homo sapiens	222-241
24025984-1	2014	We previously reported that aging and/or cytochrome P450 2D6 polymorphism are responsible for the interindividual variability in the systemic clearance (CL) and bioavailability (F) of metoprolol.	Metoprolol	184-194	cytochrome P450 2D6	Homo sapiens	41-60
23984327-6	2013	These substances were inactivated by cytochrome P450 2D6 through N-demethylation and aromatic hydroxylation (MPTP) and aromatic hydroxylation (2-methyltetrahydro-beta-carboline).	Nitrogen	65-66	cytochrome P450 2D6	Homo sapiens	37-56
23514553-0	2013	Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol.	Metoprolol	94-104	cytochrome P450 2D6	Homo sapiens	0-19
23984327-6	2013	These substances were inactivated by cytochrome P450 2D6 through N-demethylation and aromatic hydroxylation (MPTP) and aromatic hydroxylation (2-methyltetrahydro-beta-carboline).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	109-113	cytochrome P450 2D6	Homo sapiens	37-56
23514553-1	2013	OBJECTIVE: The aim was to compare cytochrome P450 2D6 phenotype and genotype using metoprolol as a probe drug.	Metoprolol	83-93	cytochrome P450 2D6	Homo sapiens	34-53
23514553-3	2013	BACKGROUND: Cytochrome P450 2D6 is a highly polymorphic enzyme that contributes to the variability of metoprolol.	Metoprolol	102-112	cytochrome P450 2D6	Homo sapiens	12-31
23984327-6	2013	These substances were inactivated by cytochrome P450 2D6 through N-demethylation and aromatic hydroxylation (MPTP) and aromatic hydroxylation (2-methyltetrahydro-beta-carboline).	2-methyltryptoline	143-176	cytochrome P450 2D6	Homo sapiens	37-56
22506851-5	2012	We present evidence that cytochrome P450 2D6 catalyzes the formation of 7-hydroxyquetiapine, which can be oxidized by human myeloperoxidase to form a reactive quinone-imine and a reactive radical, which may account for the continued, although reduced, neutrophil toxicity.	7-Hydroxy Quetiapine	72-91	cytochrome P450 2D6	Homo sapiens	25-44
23086294-0	2012	Rationalization of stereospecific binding of propranolol to cytochrome P450 2D6 by free energy calculations.	Propranolol	45-56	cytochrome P450 2D6	Homo sapiens	60-79
22749259-7	2012	RESULTS: TBZ variably undergoes extensive first-pass metabolism to active metabolites, some of which are metabolized by the cytochrome P450 2D6 isozyme.	Tetrabenazine	9-12	cytochrome P450 2D6	Homo sapiens	124-143
22506851-5	2012	We present evidence that cytochrome P450 2D6 catalyzes the formation of 7-hydroxyquetiapine, which can be oxidized by human myeloperoxidase to form a reactive quinone-imine and a reactive radical, which may account for the continued, although reduced, neutrophil toxicity.	quinone-imine	159-172	cytochrome P450 2D6	Homo sapiens	25-44
20709477-4	2010	Polymorphisms of the cytochrome P 450 2D6 influence the metabolism of many drugs including the analgesics codeine, tramadol, hydrocodone and oxycodone, as well as the metabolism of tricyclic antidepressants and the anticancer drug tamoxifen.	Codeine	106-113	cytochrome P450 2D6	Homo sapiens	21-41
20709477-4	2010	Polymorphisms of the cytochrome P 450 2D6 influence the metabolism of many drugs including the analgesics codeine, tramadol, hydrocodone and oxycodone, as well as the metabolism of tricyclic antidepressants and the anticancer drug tamoxifen.	Tramadol	115-123	cytochrome P450 2D6	Homo sapiens	21-41
20709477-4	2010	Polymorphisms of the cytochrome P 450 2D6 influence the metabolism of many drugs including the analgesics codeine, tramadol, hydrocodone and oxycodone, as well as the metabolism of tricyclic antidepressants and the anticancer drug tamoxifen.	Hydrocodone	125-136	cytochrome P450 2D6	Homo sapiens	21-41
20709477-4	2010	Polymorphisms of the cytochrome P 450 2D6 influence the metabolism of many drugs including the analgesics codeine, tramadol, hydrocodone and oxycodone, as well as the metabolism of tricyclic antidepressants and the anticancer drug tamoxifen.	Oxycodone	141-150	cytochrome P450 2D6	Homo sapiens	21-41
20709477-4	2010	Polymorphisms of the cytochrome P 450 2D6 influence the metabolism of many drugs including the analgesics codeine, tramadol, hydrocodone and oxycodone, as well as the metabolism of tricyclic antidepressants and the anticancer drug tamoxifen.	Tamoxifen	231-240	cytochrome P450 2D6	Homo sapiens	21-41
20175668-5	2010	CONCLUSIONS: Our observations of symptoms of zuclopenthixol toxicity are consistent with a cytochrome P450 2D6/3A4 interaction with fluoxetine.	Fluoxetine	132-142	cytochrome P450 2D6	Homo sapiens	91-110
21068648-8	2010	These findings suggest that cyamemazine inhibits the 9-hydroxylation of risperidone and is probably an inhibitor of cytochrome P450 2D6 as are many other phenothiazine drugs.	cyamemazine	28-39	cytochrome P450 2D6	Homo sapiens	116-135
20441720-0	2010	Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.	Venlafaxine Hydrochloride	66-77	cytochrome P450 2D6	Homo sapiens	0-19
20441720-1	2010	INTRODUCTION: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV).	Venlafaxine Hydrochloride	14-25	cytochrome P450 2D6	Homo sapiens	121-140
20441720-1	2010	INTRODUCTION: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV).	serotonin-norepinephrine	29-53	cytochrome P450 2D6	Homo sapiens	121-140
20441720-1	2010	INTRODUCTION: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV).	Desvenlafaxine Succinate	153-175	cytochrome P450 2D6	Homo sapiens	121-140
20441720-1	2010	INTRODUCTION: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor antidepressant, is metabolized primarily by the cytochrome P450 2D6 enzyme into O-desmethylvenlafaxine (ODV).	Desvenlafaxine Succinate	177-180	cytochrome P450 2D6	Homo sapiens	121-140
20194144-8	2010	Patients who lack cytochrome P450 2D6 isoenzyme activity are prone to adverse effects of TCAs and venlafaxine and have a weaker analgesic response to tramadol.	Venlafaxine Hydrochloride	98-109	cytochrome P450 2D6	Homo sapiens	18-37
20194144-8	2010	Patients who lack cytochrome P450 2D6 isoenzyme activity are prone to adverse effects of TCAs and venlafaxine and have a weaker analgesic response to tramadol.	Tramadol	150-158	cytochrome P450 2D6	Homo sapiens	18-37
18663559-7	2009	Three poor metabolizers of cytochrome P450 2D6 had higher plasma taurine areas under the curve than 27 extensive metabolizers.	Taurine	65-72	cytochrome P450 2D6	Homo sapiens	27-46
19171674-2	2009	We previously reported that the human cytochromes P450 2D6, 3A4, and 4F2 are high-affinity, high-turnover anandamide oxygenases in vitro, forming the novel metabolites hydroxyeicosatetraenoic acid ethanolamides and epoxyeicosatrienoic acid ethanolamides.	hydroxyeicosatetraenoic acid ethanolamides	168-210	cytochrome P450 2D6	Homo sapiens	38-63
19171674-2	2009	We previously reported that the human cytochromes P450 2D6, 3A4, and 4F2 are high-affinity, high-turnover anandamide oxygenases in vitro, forming the novel metabolites hydroxyeicosatetraenoic acid ethanolamides and epoxyeicosatrienoic acid ethanolamides.	epoxyeicosatrienoic acid ethanolamides	215-253	cytochrome P450 2D6	Homo sapiens	38-63
19899781-0	2010	Role of water in molecular docking simulations of cytochrome P450 2D6.	Water	8-13	cytochrome P450 2D6	Homo sapiens	50-69
19899781-3	2010	In this study, the effects of including water molecules in molecular docking simulations of the important metabolic enzyme cytochrome P450 2D6 are investigated.	Water	40-45	cytochrome P450 2D6	Homo sapiens	123-142
19853725-21	2009	CONCLUSION: We hypothesise that cytochrome P450 2D6 is implicated in this case-report because it is active in metabolizing aripiprazole.	Aripiprazole	123-135	cytochrome P450 2D6	Homo sapiens	32-51
19417618-1	2009	BACKGROUND: Oxycodone is a mu-opioid receptor agonist that is metabolized mainly in the liver by cytochrome P450 3A and 2D6 enzymes.	Oxycodone	12-21	cytochrome P450 2D6	Homo sapiens	97-123
18663559-8	2009	Hypothetically, cytochrome P450 2D6 influences the transport of taurine across the blood-brain barrier.	Taurine	64-71	cytochrome P450 2D6	Homo sapiens	16-35
18563832-9	2009	All the 4-aminoquinolines inhibited recombinant human cytochrome P450 2D6 with similar potency; DEI also inhibited 1A2.	4-aminoquinoline	8-25	cytochrome P450 2D6	Homo sapiens	54-73
19142106-1	2009	BACKGROUND: The goal of this study was to evaluate the impact of cytochrome P450 2D6 extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single doses of venlafaxine extended release (ER) and desvenlafaxine (administered as desvenlafaxine succinate) in healthy adults.	Venlafaxine Hydrochloride	187-198	cytochrome P450 2D6	Homo sapiens	65-84
16352597-1	2006	Cytochrome P450 2D6 is a heme-containing enzyme that is responsible for the metabolism of at least 20% of known drugs.	Heme	25-29	cytochrome P450 2D6	Homo sapiens	0-19
17403378-5	2007	A well-documented example of ADME gene variation is the debrisoquine polymorphism, which is characterized by markedly different metabolism of numerous commonly prescribed drugs based on variants of the cytochrome P450 2D6 gene.	Debrisoquin	56-68	cytochrome P450 2D6	Homo sapiens	202-221
16534635-0	2006	Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.	Risperidone	48-59	cytochrome P450 2D6	Homo sapiens	0-19
16534635-0	2006	Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.	metylperon	76-85	cytochrome P450 2D6	Homo sapiens	0-19
18665165-2	2008	Cytochrome P-450 2D6 metabolizes tamoxifen to metabolites that more readily bind the oestrogen receptor.	Tamoxifen	33-42	cytochrome P450 2D6	Homo sapiens	0-20
18840027-11	2008	The model detected high variability of the intrinsic clearance of venlafaxine (94.8%), most likely due to cytochrome P450 2D6 polymorphism.	Venlafaxine Hydrochloride	66-77	cytochrome P450 2D6	Homo sapiens	106-125
17803873-1	2007	OBJECTIVE: To determine whether the presence or absence of a fully functioning cytochrome P450 2D6 allele was associated with the dosage of the antidepressant drug venlafaxine in patients who had either adverse effects or absence of a therapeutic response to treatment with the immediate release or extended release form of venlafaxine.	Venlafaxine Hydrochloride	164-175	cytochrome P450 2D6	Homo sapiens	79-98
17224704-0	2007	Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer.	Atomoxetine Hydrochloride	21-32	cytochrome P450 2D6	Homo sapiens	58-77
17224704-0	2007	Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer.	Methylphenidate	37-52	cytochrome P450 2D6	Homo sapiens	58-77
17224709-0	2007	Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.	Duloxetine Hydrochloride	14-24	cytochrome P450 2D6	Homo sapiens	66-85
17224709-0	2007	Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.	Sertraline	44-54	cytochrome P450 2D6	Homo sapiens	66-85
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Duloxetine Hydrochloride	68-78	cytochrome P450 2D6	Homo sapiens	161-180
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Duloxetine Hydrochloride	68-78	cytochrome P450 2D6	Homo sapiens	242-261
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Citalopram	80-92	cytochrome P450 2D6	Homo sapiens	161-180
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Sertraline	98-108	cytochrome P450 2D6	Homo sapiens	161-180
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Sertraline	98-108	cytochrome P450 2D6	Homo sapiens	242-261
17224709-1	2007	This study is the first to directly compare the relative effects of duloxetine, escitalopram, and sertraline on the functional activity of the drug-metabolizing cytochrome P450 2D6 enzyme as assessed by changes in the pharmacokinetics of the cytochrome P450 2D6 model substrate drug, metoprolol.	Metoprolol	284-294	cytochrome P450 2D6	Homo sapiens	161-180
17872605-4	2007	ANSWER: When a mother is an ultrarapid metabolizer of cytochrome P450 2D6, she produces much more morphine when taking codeine than most people do.	Morphine	98-106	cytochrome P450 2D6	Homo sapiens	54-73
17872605-4	2007	ANSWER: When a mother is an ultrarapid metabolizer of cytochrome P450 2D6, she produces much more morphine when taking codeine than most people do.	Codeine	119-126	cytochrome P450 2D6	Homo sapiens	54-73
16342006-12	2005	This commonly used comedication could have led to an aggravation of the problem because (1) most SSRIs stimulate prolactin secretion and (2) trimipramine is metabolized by the cytochrome P450 2D6, which in turn is inhibited by all SSRIs, thus potentially leading to elevated trimipramine plasma levels.	Trimipramine	141-153	cytochrome P450 2D6	Homo sapiens	176-195
16542048-11	2006	Caution should also be exercised when prescribing strong cytochrome P450 2D6 inhibitors, such as paroxetine or fluoxetine, to women who are taking tamoxifen.	Paroxetine	97-107	cytochrome P450 2D6	Homo sapiens	57-76
16542048-11	2006	Caution should also be exercised when prescribing strong cytochrome P450 2D6 inhibitors, such as paroxetine or fluoxetine, to women who are taking tamoxifen.	Fluoxetine	111-121	cytochrome P450 2D6	Homo sapiens	57-76
16542048-11	2006	Caution should also be exercised when prescribing strong cytochrome P450 2D6 inhibitors, such as paroxetine or fluoxetine, to women who are taking tamoxifen.	Tamoxifen	147-156	cytochrome P450 2D6	Homo sapiens	57-76
16342006-12	2005	This commonly used comedication could have led to an aggravation of the problem because (1) most SSRIs stimulate prolactin secretion and (2) trimipramine is metabolized by the cytochrome P450 2D6, which in turn is inhibited by all SSRIs, thus potentially leading to elevated trimipramine plasma levels.	Trimipramine	275-287	cytochrome P450 2D6	Homo sapiens	176-195
15602102-10	2004	The role of bupropion in SS is possibly related to its well-established specific inhibition of the cytochrome P450 2D6 pathway, increasing blood levels of SSRIs and tricyclic antidepressants.	Bupropion	12-21	cytochrome P450 2D6	Homo sapiens	99-118
16129989-5	2005	Cytochrome P-450 2D6 slow metabolizers derived greater analgesia from tramadol and less from amitriptyline compared with fast metabolizers in the first treatment week (P < 0.01).	Tramadol	70-78	cytochrome P450 2D6	Homo sapiens	0-20
16129989-5	2005	Cytochrome P-450 2D6 slow metabolizers derived greater analgesia from tramadol and less from amitriptyline compared with fast metabolizers in the first treatment week (P < 0.01).	Amitriptyline	93-106	cytochrome P450 2D6	Homo sapiens	0-20
15970126-1	2005	We analyzed cytochrome P450 2D6 polymorphism by determining phenotype as the metabolic ratio between dextromethorphan and its main metabolite, dextrorphan.	Dextromethorphan	101-117	cytochrome P450 2D6	Homo sapiens	12-31
15970126-1	2005	We analyzed cytochrome P450 2D6 polymorphism by determining phenotype as the metabolic ratio between dextromethorphan and its main metabolite, dextrorphan.	Dextrorphan	143-154	cytochrome P450 2D6	Homo sapiens	12-31
15767244-3	2005	In humans, risperidone is metabolized by cytochrome P450 2D6 to 9-hydroxyrisperidone; together these constitute the active moiety.	Risperidone	11-22	cytochrome P450 2D6	Homo sapiens	41-60
15767244-3	2005	In humans, risperidone is metabolized by cytochrome P450 2D6 to 9-hydroxyrisperidone; together these constitute the active moiety.	Paliperidone Palmitate	64-84	cytochrome P450 2D6	Homo sapiens	41-60
12673723-9	2003	The cytochrome P450 2D6 locus, known to be mutated at high frequencies in NF2 patients and to be specifically inhibited by quinidine, was screened for mutations by cycle sequencing.	Quinidine	123-132	cytochrome P450 2D6	Homo sapiens	4-23
14967005-0	2004	Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.	1-((2-ethyl-4-methyl-1H-imidazol-5-yl)methyl)-4-(4-(trifluoromethyl)-2-pyridinyl)piperazine	55-147	cytochrome P450 2D6	Homo sapiens	32-51
14967005-1	2004	The kinetics for inactivation of cytochrome P450 2D6 by (1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine (EMTPP) were characterized, and the mechanism was determined in an effort to understand the observed time-based inactivation.	1-((2-ethyl-4-methyl-1H-imidazol-5-yl)methyl)-4-(4-(trifluoromethyl)-2-pyridinyl)piperazine	56-148	cytochrome P450 2D6	Homo sapiens	33-52
14967005-1	2004	The kinetics for inactivation of cytochrome P450 2D6 by (1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine (EMTPP) were characterized, and the mechanism was determined in an effort to understand the observed time-based inactivation.	1-((2-ethyl-4-methyl-1H-imidazol-5-yl)methyl)-4-(4-(trifluoromethyl)-2-pyridinyl)piperazine	150-155	cytochrome P450 2D6	Homo sapiens	33-52
14600248-1	2004	Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450-2D6, which catalyzes O-demethylation of codeine to morphine.	Codeine	51-58	cytochrome P450 2D6	Homo sapiens	109-128
14600248-1	2004	Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450-2D6, which catalyzes O-demethylation of codeine to morphine.	3-methoxymorphine	60-77	cytochrome P450 2D6	Homo sapiens	109-128
14600248-1	2004	Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450-2D6, which catalyzes O-demethylation of codeine to morphine.	Codeine	165-172	cytochrome P450 2D6	Homo sapiens	109-128
14600248-1	2004	Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450-2D6, which catalyzes O-demethylation of codeine to morphine.	Morphine	69-77	cytochrome P450 2D6	Homo sapiens	109-128
11714275-0	2001	Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis.	phenethylamine	13-27	cytochrome P450 2D6	Homo sapiens	43-62
12093814-0	2002	Oxidation of methoxyphenethylamines by cytochrome P450 2D6.	methoxyphenethylamines	13-35	cytochrome P450 2D6	Homo sapiens	39-58
14566199-4	2003	The role of paroxetine in clinically significant drug-drug interactions, especially involving metabolic inhibitory effects on the substrates of cytochrome p450 2D6, has long been suspected, but only isolated cases provide any evidence.	Paroxetine	12-22	cytochrome P450 2D6	Homo sapiens	144-163
12616671-2	2003	Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy.	Risperidone	0-11	cytochrome P450 2D6	Homo sapiens	55-74
12616671-2	2003	Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy.	Donepezil	16-25	cytochrome P450 2D6	Homo sapiens	55-74
11270921-7	2001	These results confirm the involvement of cytochrome P450 2D6 in methadone metabolism.	Methadone	64-73	cytochrome P450 2D6	Homo sapiens	41-60
11599617-11	2001	The primary metabolite of PMA is produced by O-demethylation to 4-hydroxyamphetamine, a reaction catalyzed by cytochrome P450 2D6.	4-methoxyamphetamine	26-29	cytochrome P450 2D6	Homo sapiens	110-129
11599617-11	2001	The primary metabolite of PMA is produced by O-demethylation to 4-hydroxyamphetamine, a reaction catalyzed by cytochrome P450 2D6.	p-Hydroxyamphetamine	64-84	cytochrome P450 2D6	Homo sapiens	110-129
11556812-0	2001	Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.	bufuralol	92-101	cytochrome P450 2D6	Homo sapiens	27-46
11517168-2	2001	In this study we demonstrated that recombinant rat cytochrome P450 2D1 and 2D4 and human cytochrome P450 2D6 possess progesterone 6 beta- and 16 alpha- hydroxylation activities; 2 beta- and 21-hydroxylation activities; and 2 beta-, 6 beta-, 16 alpha- and 21-hydroxylation activities, respectively.	Progesterone	117-129	cytochrome P450 2D6	Homo sapiens	89-108
12404553-1	2001	Paroxetine inhibits cytochrome P(450) 2D6, which is involved in the metabolism of mirtazapine.	Paroxetine	0-10	cytochrome P450 2D6	Homo sapiens	20-41
12404553-1	2001	Paroxetine inhibits cytochrome P(450) 2D6, which is involved in the metabolism of mirtazapine.	Mirtazapine	82-93	cytochrome P450 2D6	Homo sapiens	20-41
11355862-0	2001	Coumarin substrates for cytochrome P450 2D6 fluorescence assays.	coumarin	0-8	cytochrome P450 2D6	Homo sapiens	24-43
11355862-1	2001	A set of nine 4-aminomethyl-7-alkoxycoumarin derivatives was synthesized and characterized as substrates for O-dealkylation by recombinant cytochrome P450 2D6, a major human enzyme involved in drug metabolism.	4-aminomethyl-7-alkoxycoumarin	14-44	cytochrome P450 2D6	Homo sapiens	139-158
10424295-0	1999	Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson"s disease -- possible association with a steroid-resistant transplant rejection episode.	Steroids	147-154	cytochrome P450 2D6	Homo sapiens	15-34
10409393-0	1999	Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening.	7-methoxy-4-(aminomethyl)coumarin	43-76	cytochrome P450 2D6	Homo sapiens	102-121
10424295-1	1999	BACKGROUND/AIMS: Antibodies to cytochrome P450 2D6, also known as LKM1-autoantibodies, are characteristic for a subgroup of patients with autoimmune hepatitis, but can also occasionally be found in hepatitis C. We observed the occurrence of LKM1-autoantibodies 4 months after liver transplantation for Wilson"s disease, in close association with a steroid-resistant rejection episode, in the absence of evidence for autoimmune hepatitis or hepatitis C. METHODS: Sera from several time points prior to and following transplantation were tested for LKM-reactivity by immunofluorescence, ELISA and Western blotting.	Steroids	348-355	cytochrome P450 2D6	Homo sapiens	31-50
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	Metoprolol	0-10	cytochrome P450 2D6	Homo sapiens	176-194
9763403-0	1998	Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers.	morin	39-41	cytochrome P450 2D6	Homo sapiens	81-100
9758674-0	1998	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.	Desipramine	14-25	cytochrome P450 2D6	Homo sapiens	41-60
9758674-0	1998	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.	Quinidine	74-83	cytochrome P450 2D6	Homo sapiens	41-60
9758674-3	1998	Biotransformation of desipramine (DMI) to hydroxydesipramine (OH-DMI), an index reaction used to profile activity of human cytochrome P450-2D6, was studied in vitro using human liver microsomes.	Desipramine	34-37	cytochrome P450 2D6	Homo sapiens	123-142
9663813-2	1998	AIMS: Dihydrocodeine is metabolized to dihydromorphine via the isoenzyme cytochrome P450 2D6, whose activity is determined by genetic polymorphism.	dihydrocodeine	6-20	cytochrome P450 2D6	Homo sapiens	73-92
9663813-2	1998	AIMS: Dihydrocodeine is metabolized to dihydromorphine via the isoenzyme cytochrome P450 2D6, whose activity is determined by genetic polymorphism.	Dihydromorphine	39-54	cytochrome P450 2D6	Homo sapiens	73-92
9442550-5	1997	With regard to interactions of SSRIs and clozapine, fluvoxamine, a potent inhibitor of cytochrome P450 1A2, gives rise to higher clozapine levels at an earlier time, compared to other SSRIs (paroxetine, fluoxetine and sertraline), which are potent cytochrome P450 2D6 inhibitors.	Fluvoxamine	52-63	cytochrome P450 2D6	Homo sapiens	248-267
9165554-3	1997	Venlafaxine inhibits the cytochrome P-450 2D6 isozyme to a lesser extent than the selective serotonin reuptake inhibitors (SSRIs) and is 27% protein bound.	Venlafaxine Hydrochloride	0-11	cytochrome P450 2D6	Homo sapiens	25-45
9579300-6	1998	Since the patient was genotypically and phenotypically a cytochrome P450 2D6 poor metabolizer, the authors attribute the relevant pharmacokinetic interaction to another clomipramine-metabolizing enzyme.	Clomipramine	169-181	cytochrome P450 2D6	Homo sapiens	57-76
9109653-0	1997	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-44	cytochrome P450 2D6	Homo sapiens	63-82
9109653-1	1997	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that produces Parkinsonism symptoms in man, has been examined as a substrate of recombinant human cytochrome P450 2D6.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-44	cytochrome P450 2D6	Homo sapiens	164-183
9109653-1	1997	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that produces Parkinsonism symptoms in man, has been examined as a substrate of recombinant human cytochrome P450 2D6.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	46-50	cytochrome P450 2D6	Homo sapiens	164-183
9103485-0	1997	Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.	Hydrocodone	48-59	cytochrome P450 2D6	Homo sapiens	14-33
9103485-0	1997	Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.	Hydromorphone	63-76	cytochrome P450 2D6	Homo sapiens	14-33
9103485-1	1997	Enzymatic conversion of hydrocodone to hydromorphone is catalyzed by cytochrome P450 2D6, which is inactive in about 7% of Caucasians [poor metabolizers (PMs)] and can be inhibited by quinidine pretreatment in the remainder [extensive metabolizers (EMs)].	Hydrocodone	24-35	cytochrome P450 2D6	Homo sapiens	69-88
9103485-1	1997	Enzymatic conversion of hydrocodone to hydromorphone is catalyzed by cytochrome P450 2D6, which is inactive in about 7% of Caucasians [poor metabolizers (PMs)] and can be inhibited by quinidine pretreatment in the remainder [extensive metabolizers (EMs)].	Hydromorphone	39-52	cytochrome P450 2D6	Homo sapiens	69-88
9103485-1	1997	Enzymatic conversion of hydrocodone to hydromorphone is catalyzed by cytochrome P450 2D6, which is inactive in about 7% of Caucasians [poor metabolizers (PMs)] and can be inhibited by quinidine pretreatment in the remainder [extensive metabolizers (EMs)].	Quinidine	184-193	cytochrome P450 2D6	Homo sapiens	69-88
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	Indoramin	12-22	cytochrome P450 2D6	Homo sapiens	176-194
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	Codeine	24-31	cytochrome P450 2D6	Homo sapiens	176-194
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	Tamoxifen	33-42	cytochrome P450 2D6	Homo sapiens	176-194
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	prodipin	47-56	cytochrome P450 2D6	Homo sapiens	176-194
9149375-2	1997	Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6.	N-Methyl-3,4-methylenedioxyamphetamine	99-103	cytochrome P450 2D6	Homo sapiens	176-194
9149375-4	1997	For both the R- and S-enantiomer of metoprolol, the R- and S-enantiomer of MDMA, and for indoramine and codeine (all proven substrates of cytochrome P4502D6) an acceptable fit in the substrate model was obtained.	Indoramin	89-99	cytochrome P450 2D6	Homo sapiens	138-156
9149375-4	1997	For both the R- and S-enantiomer of metoprolol, the R- and S-enantiomer of MDMA, and for indoramine and codeine (all proven substrates of cytochrome P4502D6) an acceptable fit in the substrate model was obtained.	Codeine	104-111	cytochrome P450 2D6	Homo sapiens	138-156
8848008-0	1995	Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.	Sparteine	43-52	cytochrome P450 2D6	Homo sapiens	13-32
8951188-19	1996	These results indicate that the conversion of mCPP to p-HO-mCPP is attributable to metabolism by cytochrome P450 2D6.	1-(3-chlorophenyl)piperazine	46-50	cytochrome P450 2D6	Homo sapiens	97-116
8951188-19	1996	These results indicate that the conversion of mCPP to p-HO-mCPP is attributable to metabolism by cytochrome P450 2D6.	p-ho-mcpp	54-63	cytochrome P450 2D6	Homo sapiens	97-116
8861776-4	1996	For example, fluoxetine and paroxetine produce clinically significant inhibition of cytochrome P450 2D6 at their usually effective antidepressant dose, whereas citalopram, fluvoxamine or sertraline do not.	Fluoxetine	13-23	cytochrome P450 2D6	Homo sapiens	84-103
8861776-4	1996	For example, fluoxetine and paroxetine produce clinically significant inhibition of cytochrome P450 2D6 at their usually effective antidepressant dose, whereas citalopram, fluvoxamine or sertraline do not.	Paroxetine	28-38	cytochrome P450 2D6	Homo sapiens	84-103
8791777-0	1996	Measurement of human liver microsomal cytochrome P450 2D6 activity using [O-methyl-14C]dextromethorphan as substrate.	[o-methyl-14c]dextromethorphan	73-103	cytochrome P450 2D6	Homo sapiens	38-57
8848008-1	1995	Two different reaction mechanisms for the formation of the two human enamine-structured sparteine metabolites by cytochrome P450 2D6 have been discussed in the literature.	cyclopentyl enamine	69-76	cytochrome P450 2D6	Homo sapiens	113-132
8848008-1	1995	Two different reaction mechanisms for the formation of the two human enamine-structured sparteine metabolites by cytochrome P450 2D6 have been discussed in the literature.	Sparteine	88-97	cytochrome P450 2D6	Homo sapiens	113-132
8848008-7	1995	However, results of competitive and noncompetitive experiments revealed the presence of a nondissociative enzymatic mechanism for the formation of the two sparteine metabolites, i.e., the sparteine molecule that is bound to the substrate binding site of cytochrome P450 2D6 performs orientational changes without dissociating from the activated enzyme/substrate complex before the product-determining first irreversible reaction step.	Sparteine	155-164	cytochrome P450 2D6	Homo sapiens	254-273
8848008-7	1995	However, results of competitive and noncompetitive experiments revealed the presence of a nondissociative enzymatic mechanism for the formation of the two sparteine metabolites, i.e., the sparteine molecule that is bound to the substrate binding site of cytochrome P450 2D6 performs orientational changes without dissociating from the activated enzyme/substrate complex before the product-determining first irreversible reaction step.	Sparteine	188-197	cytochrome P450 2D6	Homo sapiens	254-273
7663530-0	1995	The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.	Dextromethorphan	44-60	cytochrome P450 2D6	Homo sapiens	62-81
7624929-6	1995	Zuclopenthixol, on the other hand, does not exert any impact under routine therapeutic drug monitoring, even though the drug is known to partly depend on metabolism by the isozyme cytochrome P450 2D6.	Clopenthixol	0-14	cytochrome P450 2D6	Homo sapiens	180-199
1611804-0	1992	Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.	Dextromethorphan	0-16	cytochrome P450 2D6	Homo sapiens	106-124
8138941-5	1994	Quinidine was a highly potent inhibitor of 2-OH-DMI formation (mean Ki = 0.053 microM), consistent with the presumed role of Cytochrome P450-2D6 in mediating this reaction.	Quinidine	0-9	cytochrome P450 2D6	Homo sapiens	125-144
8363993-4	1993	In man, tropisetron metabolism is linked to the cytochrome P-450 2D6 isoenzyme system, which determines the polymorphism of debrisoquine/sparteine metabolism.	Tropisetron	8-19	cytochrome P450 2D6	Homo sapiens	48-68
8363993-4	1993	In man, tropisetron metabolism is linked to the cytochrome P-450 2D6 isoenzyme system, which determines the polymorphism of debrisoquine/sparteine metabolism.	Debrisoquin	124-136	cytochrome P450 2D6	Homo sapiens	48-68
8363993-4	1993	In man, tropisetron metabolism is linked to the cytochrome P-450 2D6 isoenzyme system, which determines the polymorphism of debrisoquine/sparteine metabolism.	Sparteine	137-146	cytochrome P450 2D6	Homo sapiens	48-68
1611804-7	1992	Based on the brain/plasma ratio for dextromethorphan in rats, it is estimated that brain dextromethorphan concentrations of 1.0 to 10 micrograms/gm may be attainable in humans by inhibition of cytochrome P4502D6 activity with quinidine.	Dextromethorphan	89-105	cytochrome P450 2D6	Homo sapiens	193-211
1611804-7	1992	Based on the brain/plasma ratio for dextromethorphan in rats, it is estimated that brain dextromethorphan concentrations of 1.0 to 10 micrograms/gm may be attainable in humans by inhibition of cytochrome P4502D6 activity with quinidine.	Gentamicins	145-147	cytochrome P450 2D6	Homo sapiens	193-211
1611804-7	1992	Based on the brain/plasma ratio for dextromethorphan in rats, it is estimated that brain dextromethorphan concentrations of 1.0 to 10 micrograms/gm may be attainable in humans by inhibition of cytochrome P4502D6 activity with quinidine.	Quinidine	226-235	cytochrome P450 2D6	Homo sapiens	193-211
1379482-1	1992	Molecular modeling techniques were used to derive a predictive model for substrates of cytochrome P450 2D6, an isozyme known to metabolize only compounds with one or more basic nitrogen atoms.	Nitrogen	177-185	cytochrome P450 2D6	Homo sapiens	87-106
1611804-0	1992	Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6.	Quinidine	73-82	cytochrome P450 2D6	Homo sapiens	106-124
1611804-3	1992	The purpose of this research was to determine whether quinidine (a selective inhibitor of cytochrome P4502D6) could improve dextromethorphan systemic delivery in patients with amyotrophic lateral sclerosis (a neurodegenerative disease).	Quinidine	54-63	cytochrome P450 2D6	Homo sapiens	90-108
1611804-3	1992	The purpose of this research was to determine whether quinidine (a selective inhibitor of cytochrome P4502D6) could improve dextromethorphan systemic delivery in patients with amyotrophic lateral sclerosis (a neurodegenerative disease).	Dextromethorphan	124-140	cytochrome P450 2D6	Homo sapiens	90-108